Synmosa Biopharma Corporation

NT$27.20As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4114Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR 10.53%
Div yield 2.89%
ROE 5.91%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) —
PE TTM 17.80
TSR TTM (10.16%)
Mkt cap NT$14.72B
ROIC 5.25%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$31
15.68%
(54.75%)
Hold 2|12|3|8|0
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.59
0.58
0.57
0.63
5.13%
1.66%
(7.55%)
1.75%
RevenueNT$M
770.7
791.5
811.5
823.2
(4.25%)
1.02%
5.32%
7.60%
Peers (US$444.5M)
Cap (US$)
PE
473.0M
17.48x
Capital
TTM
5Y
10Y
Leveragex
0.926
0.274
0.215
EBIT/Intx
1.463
0.192
0.194
Own earn%
73.14
37.86
33.68
Sh yield%
19.06
38.84
37.55
Owners
Insiders/Inst%
7.23
45.09
Short interest%
1.76
SBC / revenue%
0.79
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
14–23
$1 testx
0.1
Incr. ROIC%
6